Cartesian Therapeutics, Inc.
RNAC
$6.65
-$0.06-0.89%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.09M | 1.03M | 34.17M | 38.91M | 47.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.09M | 1.03M | 34.17M | 38.91M | 47.94M |
| Cost of Revenue | 27.19M | 24.99M | 23.96M | 23.40M | 28.34M |
| Gross Profit | -26.10M | -23.97M | 10.22M | 15.52M | 19.60M |
| SG&A Expenses | 30.36M | 29.20M | 28.99M | 29.53M | 38.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.01M | 81.45M | 79.03M | 74.43M | 88.63M |
| Operating Income | -83.92M | -80.43M | -44.86M | -35.52M | -40.69M |
| Income Before Tax | -47.69M | -35.97M | -38.02M | -77.14M | -263.83M |
| Income Tax Expenses | 287.00K | 287.00K | 287.00K | 287.00K | -19.00M |
| Earnings from Continuing Operations | -47.98 | -36.26 | -38.31 | -77.42 | -244.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.98M | -36.26M | -38.31M | -77.42M | -244.83M |
| EBIT | -83.92M | -80.43M | -44.86M | -35.52M | -40.69M |
| EBITDA | -81.08M | -77.91M | -42.74M | -34.37M | -39.75M |
| EPS Basic | -1.86 | -1.60 | -1.54 | -10.67 | -50.92 |
| Normalized Basic EPS | -1.79 | -1.59 | -0.70 | -2.20 | -21.41 |
| EPS Diluted | -1.88 | -1.62 | -1.58 | -10.72 | -50.96 |
| Normalized Diluted EPS | -1.78 | -1.59 | -0.73 | -2.22 | -21.43 |
| Average Basic Shares Outstanding | 103.31M | 98.78M | 89.52M | 69.03M | 48.90M |
| Average Diluted Shares Outstanding | 103.78M | 99.24M | 90.59M | 70.10M | 49.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |